Collagenase-assisted wound bed preparation: An in vitro comparison between Vibrio alginolyticus and Clostridium histolyticum collagenases on substrate specificity.


Journal

International wound journal
ISSN: 1742-481X
Titre abrégé: Int Wound J
Pays: England
ID NLM: 101230907

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 24 01 2019
revised: 02 05 2019
accepted: 11 05 2019
pubmed: 31 5 2019
medline: 21 1 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

Bacterial collagenase from the aerobic non-pathogenic Vibrio alginolyticus chemovar iophagus is an extracellular metalloproteinase. This collagenase preparation is obtained through a fermentation process and is purified chromatographically, resulting in a highly purified 82-kDa single-band protein that does not contain non-specific proteases or other microbial impurities. V. alginolyticus collagenase was added to a hyaluronan (HA)-based device to develop a novel debriding agent to improve the treatment of ulcers, necrotic burns, and decubitus in the initial phase of wound bed preparation. In this study, an in vitro biochemical characterisation of V. alginolyticus collagenase versus a commercial preparation from a Clostridium histolyticum strain on various dermal extracellular matrix (ECM) substrates was performed. V. alginolyticus collagenase demonstrated its ability to carry out the enzymatic cleavage of the substrate, allowing a selective removal of necrotic tissues while sparing healthy tissue, as reported in clinical studies and through routine clinical experience. in vitro tests under physiological conditions (pH, presence of Ca++, etc.) have demonstrated that V. alginolyticus collagenase exhibits very poor/limited non-specific proteolytic activity, whereas the collagenase preparation from C. histolyticum is highly active both on collagen and on non-collagenic substrates. This finding implies that while the V. alginolyticus enzyme is fully active on the collagen filaments that anchor the necrotic tissue to the wound bed, it does not degrade other minor, but structurally important, components of the dermal ECM. This feature could explain why collagenase preparation from V. alginolyticus has been reported to be much gentler on perilesional, healthy skin.

Identifiants

pubmed: 31148413
doi: 10.1111/iwj.13148
pmc: PMC7948778
doi:

Substances chimiques

Collagenases EC 3.4.24.-
Microbial Collagenase EC 3.4.24.3

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1013-1023

Informations de copyright

© 2019 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Références

Int Wound J. 2016 Feb;13(1):22-6
pubmed: 24698215
Biochem J. 1992 Feb 1;281 ( Pt 3):703-8
pubmed: 1311172
Histopathology. 2000 Mar;36(3):262-72
pubmed: 10692030
J Biol Chem. 1988 Dec 25;263(36):19783-7
pubmed: 2848841
Proc Natl Acad Sci U S A. 1990 Jan;87(1):364-8
pubmed: 2153297
J Gen Physiol. 1938 Sep 20;22(1):79-89
pubmed: 19873094
Tissue Eng. 2006 Mar;12(3):601-13
pubmed: 16579693
Histopathology. 1995 May;26(5):423-31
pubmed: 7544762
Biochim Biophys Acta. 2014 Aug;1840(8):2571-80
pubmed: 24631662
Biochemistry. 1984 Jun 19;23(13):3077-85
pubmed: 6087887
Health Technol Assess. 1999;3(17 Pt 1):iii-iv, 1-78
pubmed: 10492854
Int Wound J. 2019 Aug;16(4):1013-1023
pubmed: 31148413
Biochim Biophys Acta. 1976 Mar 11;429(1):239-51
pubmed: 177067
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
PLoS One. 2012;7(11):e48351
pubmed: 23173033
J Biol Chem. 2011 Jul 8;286(27):24242-52
pubmed: 21454550
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1421-1431
pubmed: 28387882
Eur J Biochem. 1991 Oct 1;201(1):71-7
pubmed: 1915379
Annu Rev Physiol. 1997;59:63-88
pubmed: 9074757
Med Res Rev. 2002 Jul;22(4):329-72
pubmed: 12111749
Mol Cell Biochem. 1979 Jan 26;23(2):87-108
pubmed: 220520
Eur J Biochem. 1991 Oct 1;201(1):79-84
pubmed: 1655429
Mol Biol Cell. 2002 Oct;13(10):3546-59
pubmed: 12388756
J Wound Care. 2012 Mar;21(3):131-2, 134-6, 138-9
pubmed: 22399081
Int J Pept Protein Res. 1988 Jan;31(1):1-16
pubmed: 3284833
Biochemistry. 1985 Nov 5;24(23):6520-6
pubmed: 3002445
Arch Biochem Biophys. 1958 Apr;74(2):465-75
pubmed: 13534676
Int J Biol Macromol. 2018 Sep;116:801-810
pubmed: 29746969
PLoS One. 2014 Feb 13;9(2):e88479
pubmed: 24551108
Int Wound J. 2013 Apr;10(2):159-66
pubmed: 22405094
J Bacteriol. 1980 May;142(2):447-54
pubmed: 6247322
J Wound Care. 2006 May;15(5):222-7
pubmed: 16711179
J Immunol. 2008 Aug 1;181(3):2103-10
pubmed: 18641349
Matrix Biol. 2011 Jan;30(1):34-42
pubmed: 20932906
Hoppe Seylers Z Physiol Chem. 1963;333:149-51
pubmed: 14058277
Wound Repair Regen. 2014 Mar-Apr;22(2):174-86
pubmed: 24611980
Ostomy Wound Manage. 1993 Jun;39(5):61-2, 66-9
pubmed: 8397708
Matrix Suppl. 1992;1:127-33
pubmed: 1480012
Genomics. 1995 Apr 10;26(3):615-8
pubmed: 7607691
J Burns Wounds. 2005 May 17;4:e8
pubmed: 16921413
Eur Rev Med Pharmacol Sci. 2013 Oct;17(20):2721-7
pubmed: 24174353
J Am Geriatr Soc. 1975 Jan;23(1):22-30
pubmed: 162802
J Clin Invest. 1953 Dec;32(12):1323-9
pubmed: 13109000
Schweiz Rundsch Med Prax. 1988 Dec 27;77(52):1428-34
pubmed: 2851160
Appl Microbiol Biotechnol. 2004 Feb;63(5):520-6
pubmed: 14556041
J Mol Biol. 1976 Nov 5;107(3):293-305
pubmed: 187752
Surg Innov. 2016 Dec;23(6):557-562
pubmed: 27448558
Int Wound J. 2016 Dec;13(6):1111-1115
pubmed: 25649929
Biochemistry. 1984 Jun 19;23(13):3085-91
pubmed: 6087888
Eur Rev Med Pharmacol Sci. 2013 Jan;17(2):210-6
pubmed: 23377810

Auteurs

Roberta Di Pasquale (R)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Susanna Vaccaro (S)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Michele Caputo (M)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Christian Cuppari (C)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Salvatore Caruso (S)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Angela Catania (A)

LC Laboratori Campisi Campisi s.r.l, Siracusa, Italy.

Luciano Messina (L)

Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Siracusa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH